Baidu
map

GSK的COPD药物Relvar Ellipta积极临床试验结果

2016-05-30 佚名 生物谷

英国制药巨头葛兰素史克近日发布临床试验数据称,其慢性阻塞性肺病(COPD)药物Relvar Ellipta在减少患者急性发作方面,优于目前的标准疗法。 Relvar Ellipta为每日1次的吸入型糖皮质激素(ICS)糠酸氟替卡松(FF)和长效β2受体激动剂(LABA)维兰特罗(VI)的复方药物。这项包含2802名患者、名为Salford Lung Study (SLS) 的临床试验结果表明

英国制药巨头葛兰素史克近日发布临床试验数据称,其慢性阻塞性肺病(COPD)药物Relvar Ellipta在减少患者急性发作方面,优于目前的标准疗法。

Relvar Ellipta为每日1次的吸入型糖皮质激素(ICS)糠酸氟替卡松(FF)和长效β2受体激动剂(LABA)维兰特罗(VI)的复方药物。这项包含2802名患者、名为Salford Lung Study (SLS) 的临床试验结果表明,和长效毒蕈碱拮抗剂(LAMA)、长效β2受体激动剂(LABA)以及吸入性糖皮质激素(ICS)等常规标准疗法相比,在减少患者急性发作方面Relvar Ellipta的疗效更为显着。

与常规标准疗法相比,使用Relvar Ellipta (fluticasone/vilanterol, FF/VI)的COPD患者,其中至重度急性发作概率降低了8.41个百分点,具有统计学上的显着差异,而副作用的发生率和其它药物相似。

葛兰素史克新药研发部门负责人Patrick Vallance表示,公司与NHS的临床协会密切合作,从患者的日常使用出发,研究了Relvar Ellipta的安全性和有效性。为了确保Salford临床试验中的数据尽可能的真实可信,葛兰素史克作出了巨大的长期投资,用于基础设施的建设和人员培训。以目前的试验结果来看,这样的投入显然是值得的。NHS基金会的呼吸疾病专家Jrgen Vestbo也指出,通过Salford临床试验,研究人员对治疗选择、患者行为等影响慢性阻塞性肺疾病(COPD)治疗效果的因素产生了更全面更深刻的认识。

去年的一项III期临床试验中,葛兰素史克测试另一款COPD药物BREO Ellipta在降低COPD患者因心血管疾病死亡风险方面的有效性,结果显示,尽管BREO Ellipta组的全因死亡率比对照组低12.2个百分点,但是未能达到统计学上的显着性。这次的临床试验结果成功逆转了葛兰素史克COPD药物管线的负性局面。目前Relvar Ellipta已经在欧盟、美国、日本等国家和地区获批,用于慢性阻塞性肺病和哮喘的治疗。

原始出处

GSK’s Relvar Ellipta hits the mark in COPD trial

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2018-04-25 871538379

    还得投入临床应用了才知道如何

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-31 足球疯子

    多多学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-31 足球疯子

    多多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-31 lovetcm

    对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-31 沉心多思

    医学进步,大家受益

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-31 忠诚向上

    好好学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=309004, encodeId=16d33090043c, content=还得投入临床应用了才知道如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Wed Apr 25 05:47:26 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545504, encodeId=02091545504b1, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Jun 01 03:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87921, encodeId=17908e921c6, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87922, encodeId=fd8d8e922e1, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87722, encodeId=59fb8e72285, content=对于c o p d来说,一款好的药物非常关键,目前还缺少真正有效的治疗策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Tue May 31 08:44:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87714, encodeId=9f608e7143d, content=医学进步,大家受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Tue May 31 08:12:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87704, encodeId=9fc88e704be, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87674, encodeId=69a28e674a6, content=不错,多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:16:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-30 足球疯子

    不错,多多学习

    0

相关资讯

2015年15大畅销新药出炉

药物开发者经常以对病人的价值为新药的高昂价格辩护,但是很少有人怀疑新药给生物制药公司提供另一种类型的价值,也就是能够通过几年有时几十年收回高昂的研发、临床试验和商业化成本而获得利润。 尽管去年新上市的药物没有一种达到成为重磅炸弹药物所需的10亿美元销售额门槛,但是排名前五中的一种新药如果其销售额再增加1亿多美元就接近这一门槛了。2015年期间投入市场的10种新药实现1000万~1亿美

葛兰素史克和辉瑞HIV三合一药物Triumeq获FDA批准

葛兰素史克(GSK)和辉瑞(Pfizer)合资公司ViiV Healthcare 近日宣布,三合一HIV药物Triumeq(dolutegravir/abacavir/lamivudine,dolutegravir/阿巴卡韦/拉米夫定,50mg/600mg/300mg)获FDA批准,用于HIV-1感染的治疗。Triumeq是ViiV首个基于dolutegravir的固定剂量组合HIV复方片,结合了

Adimab宣布将与葛兰素史克公司合作开发双特异性抗体

随着医药研究的深入,人们越来越意识到药物的靶向性在疾病治疗中所起的重要作用。因此,具有良好靶向性的抗体药物也收到了药物研发者前所未有的重视。 抗体能够特异性、单一性的识别抗原已经成为许多人的共识。但是,对于一些疾病如肿瘤来说,单特异性的抗体可能无法很好的完成这一治疗任务。而有鉴于此,著名的生物技术公司Adimab公司将自己的研究重心放在了寻找双特异性抗体领域并建立起了独一无二的平台。 研究人员

葛兰素史克收入下滑 CEO薪酬减半

据彭博社消息,由于公司利润下跌,葛兰素史克CEO Andrew Witty去年的总酬金下降了46%,其中奖金减少51%至141万美元。 葛兰素史克今年2月公布的年报显示,2014财年公司实现收入230亿英镑(约合2220.42亿元人民币(6.2584,0.0000,0.00%)),同比下滑了3%。 葛兰素史克从2013年以来陷入中国行贿丑闻。去年9月,湖南省长沙市中级人民法院对葛兰素史克(中国

葛兰素史克反贿风暴仍将继续 被罚30亿只是坏日子开始

一张30亿元的罚单,给困扰葛兰素史克(GlaxosmithklinePLC,GSK)一年多的行贿案画上了休止符,但无论对于葛兰素史克,还是对于其它跨国药企,这都只是坏日子的开始。 葛兰素史克被罚30亿 9月19日,长沙市中级人民法院对葛兰素史克中国公司(GSKCI)以及其前中国区总经理马克锐(MarkReilly)等人对非国家工作人员行贿、非国家工作人员受贿案进行审理。葛兰素史克中国公司被判罚

葛兰素史克红斑狼疮药物Benlysta获英国NICE批准

英格兰和威尔士地区的狼疮患者近日获得好消息,50多年来,NICE终于批准了治疗狼疮的新药,这就是葛兰素史克的Benlysta(贝利木单抗),该药物早在五年前就已经在欧洲获批。 2011年,Benlysta(贝利木单抗)获得欧盟批准,用于治疗自体抗原阳性的系统性红斑狼疮。但是英国药物成本监管部门、国家卫生与临床优化研究所NICE却认为该药物的价格过于昂贵,因此迟迟没有批准。 NICE最近起草

Baidu
map
Baidu
map
Baidu
map